Atlas Trials

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes

Clinical trial NCT02305381 · COMPLETED

Trial details

NCT number
NCT02305381
Sponsor
Novo Nordisk A/S
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
DiabetesDiabetes Mellitus, Type 2
Start date
2014-12-01
Primary completion
2015-11-21
Enrollment
397

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.